{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T21:03:40Z","timestamp":1783803820206,"version":"3.55.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,11,7]],"date-time":"2013-11-07T00:00:00Z","timestamp":1383782400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/3.0\/"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1016\/j.clml.2013.09.006","type":"journal-article","created":{"date-parts":[[2013,10,2]],"date-time":"2013-10-02T04:41:47Z","timestamp":1380688907000},"page":"638-645","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Ruxolitinib for Myelofibrosis\u2013An Update of Its Clinical Effects"],"prefix":"10.1016","volume":"13","author":[{"given":"Hagop M.","family":"Kantarjian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rami S.","family":"Komrokji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben A.","family":"Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Tacke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire N.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2013.09.006_bib1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.leukres.2010.07.019","article-title":"MPN-associated myelofibrosis (MPN-MF)","volume":"35","author":"Mesa","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2013.09.006_bib2","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/sj.leu.2404914","article-title":"Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment","volume":"22","author":"Barosi","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2013.09.006_bib3","first-page":"1","article-title":"Clinical and laboratory features of myelofibrosis and limitations of current therapies","volume":"9","author":"Gregory","year":"2011","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.clml.2013.09.006_bib4","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","article-title":"Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel","volume":"110","author":"Tefferi","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.09.006_bib5","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1146\/annurev.med.60.041707.160528","article-title":"Primary myelofibrosis: update on definition, pathogenesis, and treatment","volume":"60","author":"Abdel-Wahab","year":"2009","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.clml.2013.09.006_bib6","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/ajh.22210","article-title":"Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management","volume":"86","author":"Tefferi","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2013.09.006_bib7","doi-asserted-by":"crossref","unstructured":"Mehta J, Wang H, Iqbal SU, Mesa R: Epidemiology of myeloproliferative neoplasms (MPN) in the United States [e-pub ahead of print]. Leuk Lymphoma. http:\/\/10.3109\/10428194.2013.813500. Accessed: April 15, 2013.","DOI":"10.3109\/10428194.2013.813500"},{"key":"10.1016\/j.clml.2013.09.006_bib8","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1182\/blood-2008-07-170449","article-title":"New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment","volume":"113","author":"Cervantes","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.09.006_bib9","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.mayocp.2011.11.001","article-title":"One thousand patients with primary myelofibrosis: the Mayo Clinic experience","volume":"87","author":"Tefferi","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2013.09.006_bib10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nrd3264","article-title":"Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond","volume":"10","author":"Quintas-Cardama","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.clml.2013.09.006_bib11","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/asheducation-2011.1.208","article-title":"Genetic and epigenetic complexity in myeloproliferative neoplasms","volume":"2011","author":"Cross","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2013.09.006_bib12","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","article-title":"New mutations and pathogenesis of myeloproliferative neoplasms","volume":"118","author":"Vainchenker","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.09.006_bib13","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1182\/blood.V95.1.19","article-title":"The JAK-STAT pathway in normal and perturbed hematopoiesis","volume":"95","author":"Ward","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.09.006_bib14","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s13148-011-0050-6","article-title":"Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies","volume":"2","author":"Mascarenhas","year":"2011","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.clml.2013.09.006_bib15","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1038\/leu.2010.69","article-title":"Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1","volume":"24","author":"Tefferi","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2013.09.006_bib16","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A\u00a0prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2013.09.006_bib17","doi-asserted-by":"crossref","first-page":"e57856","DOI":"10.1371\/journal.pone.0057856","article-title":"Impact of JAK2 V617F mutation on hemogram variation in patients with non-reactive elevated platelet counts","volume":"8","author":"Zhou","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2013.09.006_bib18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.leukres.2010.06.017","article-title":"JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy","volume":"35","author":"Silver","year":"2011","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2013.09.006_bib19","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2013.09.006_bib20","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1200\/JCO.2010.31.8436","article-title":"Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet","volume":"29","author":"Barbui","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.09.006_bib21","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2009-09-245837","article-title":"A\u00a0dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)","volume":"115","author":"Passamonti","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2013.09.006_bib22","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1200\/JCO.2010.32.2446","article-title":"DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status","volume":"29","author":"Gangat","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.09.006_bib23","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1182\/asheducation-2011.1.222","article-title":"Management of myelofibrosis","volume":"2011","author":"Vannucchi","year":"2011","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.clml.2013.09.006_bib24","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A\u00a0double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2013.09.006_bib25","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2013.09.006_bib26","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1111\/bjh.12375","article-title":"Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy","volume":"162","author":"Harrison","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2013.09.006_bib27","first-page":"800","article-title":"Long-term outcome of ruxolitinib treatment in patients with myelofibrosis: durable reductions in spleen volume, improvements in quality of life, and overall survival advantage in COMFORT-I","volume":"120","author":"Verstovsek","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2013.09.006_bib28","first-page":"801","article-title":"Long-term safety, efficacy, and survival Findings from Comfort-II, a phase 3 study comparing ruxolitinib with best available therapy (BAT) for the treatment of myelofibrosis (MF)","volume":"120","author":"Cervantes","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2013.09.006_bib29","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3324\/haematol.2012.083543","article-title":"JAK inhibitors: beyond spleen and symptoms?","volume":"98","author":"Cervantes","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2013.09.006_bib30","first-page":"3918","article-title":"Weight loss, splenomegaly, and hypocholesterolemia in myeloproliferative neoplasms: patterns and relevance from the pre JAK2 Inhibitor era","volume":"114","author":"Mesa","year":"2009","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2013.09.006_bib31","first-page":"2851","article-title":"Decreased levels of total or HDL cholesterol in primary myelofibrosis are associated with shortened survival: DIPSS-Plus independent prognostic value","volume":"120","author":"Sulai","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2013.09.006_bib32","first-page":"1733","article-title":"Improvement in weight and total cholesterol and their association with survival in ruxolitinib-treated patients with myelofibrosis from COMFORT-I","volume":"120","author":"Mesa","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2013.09.006_bib33","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/bjh.12274","article-title":"The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, phase III study in patients with myelofibrosis","volume":"161","author":"Verstovsek","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2013.09.006_bib34","first-page":"279","article-title":"Ruxolitinib provides reductions in splenomegaly across subgroups: an analysis of spleen response in the COMFORT-II study","volume":"118","author":"Harrison","year":"2011","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2013.09.006_bib35","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.2012.44.4489","article-title":"Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial","volume":"31","author":"Mesa","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.09.006_bib36","first-page":"1727","article-title":"Clinical benefits of ruxolitinib therapy in myelofibrosis patients with varying degrees of splenomegaly and symptoms","volume":"120","author":"Mesa","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2013.09.006_bib37","first-page":"2847","article-title":"Effect of ruxolitinib on the incidence of splenectomy in patients with myelofibrosis: a retrospective analysis of data from ruxolitinib clinical trials","volume":"120","author":"Verstovsek","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2013.09.006_bib38","unstructured":"Mesa RA, Verstovsek S, Atallah E, et\u00a0al. Relationship between ruxolitinib dose and improvements in spleen volume and symptoms in patients with myelofibrosis: results from COMFORT-I. Poster presented at: 8th Annual Hematologic Malignancies Conference; October 10-14, 2012; Houston, TX."},{"key":"10.1016\/j.clml.2013.09.006_bib39","unstructured":"Verstovsek S, Quintas-Cardama A, Mesa RA, et\u00a0al. Management of cytopenias with ruxolitinib treatment in patients with myelofibrosis. Poster presented at: 8th Annual Hematologic Malignancies Conference; October 10-14, 2012; Houston, TX."},{"key":"10.1016\/j.clml.2013.09.006_bib40","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.4065\/mcp.2011.0518","article-title":"Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis","volume":"86","author":"Tefferi","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.clml.2013.09.006_bib41","unstructured":"Jakafi (ruxolitinib) tablets [prescribing information]. Wilmington, DE: Incyte Corporation; 2013. Available at: http:\/\/www.incyte.com\/sites\/default\/files\/Jakafi_PI.pdf. Accessed: June 15, 2013."},{"issue":"suppl","key":"10.1016\/j.clml.2013.09.006_bib42","article-title":"Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy","volume":"30","author":"Verstovsek","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2013.09.006_bib43","first-page":"176","article-title":"Efficacy, hematologic effects, and dose of ruxolitinib in myelofibrosis patients with low starting platelet counts (50-100 x 109\/L): a comparison to patients with normal or high starting platelet counts","volume":"120","author":"Talpaz","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2013.09.006_bib44","first-page":"177","article-title":"Expand: a phase 1b, open-label, dose-finding study of ruxolitinib in patients with myelofibrosis and baseline platelet counts between 50 x 109\/L and 99 x 109\/L","volume":"120","author":"Harrison","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2013.09.006_bib45","article-title":"Ruxolitinib in Clinical Practice for Therapy of Myelofibrosis: Single USA Center Experience Following FDA Approval","author":"Geyer","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2013.09.006_bib46","first-page":"1747","article-title":"FDA-approved ruxolitinib in patients with myelofibrosis: the Stanford experience","volume":"120","author":"Nguyen","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2013.09.006_bib47","first-page":"2841","article-title":"Ruxolitinib therapy in myelofibrosis: Analysis of 241 patients treated in compassionate use (French \u201cATU\u201d program) by the French Intergroup of Myeloproliferative Neoplasms (FIM)","volume":"120","author":"Andreoli","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2013.09.006_bib48","first-page":"2844","article-title":"An individual patient supply program for ruxolitinib for the treatment of patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF)","volume":"120","author":"Barosi","year":"2012","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1016\/j.clml.2013.09.006_bib49","unstructured":"Press Release: Incyte Corporation: Jakafi (ruxolitinib) Prescribing Information Updated with Expanded Dosing Guidance and New Safety Information. Available at: http:\/\/finance.yahoo.com\/news\/jakafi-ruxolitinib-prescribing-information-updated-211500260.html. Accessed on: June 15,\u00a02013."}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013004278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265013004278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:24:48Z","timestamp":1761870288000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265013004278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S2152265013004278"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2013.09.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ruxolitinib for Myelofibrosis\u2013An Update of Its Clinical Effects","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2013.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}